Study tests efficacy, safety of ivermectin in childhood malaria | WHO: Long-term support needed to halt spread of Ebola in DRC | Hepatitis C drugs studied in patients with cancer
March 15, 2019
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Study tests efficacy, safety of ivermectin in childhood malaria
Data from a study published in the journal Lancet showed that repeated mass administration of the drug ivermectin, a treatment for parasite infections, resulted in a 20% reduction in the incidence of malaria in children age 5 and younger in Burkina Faso. The 18-week trial, conducted during the country's 2015 rainy season to assess ivermectin's safety and efficacy, was financed by the Bill & Melinda Gates Foundation.
OnMedica (3/14) 
LinkedIn Twitter Facebook Email
Science & Health
WHO: Long-term support needed to halt spread of Ebola in DRC
The World Health Organization said sustaining efforts to contain the Ebola virus in the Democratic Republic of Congo will take additional donations of $148 million over the next six months. The CDC announced plans to send experts to provide training.
Reuters (3/14),  The Washington Post (tiered subscription model) (3/14) 
LinkedIn Twitter Facebook Email
Hepatitis C drugs studied in patients with cancer
Researchers conducted a trial to test direct-acting antivirals in cancer patients with hepatitis C virus infections and found that sofosbuvir-based therapies are safe and effective to use in this patient population, making them eligible to participate in chemotherapeutic studies. Research findings were published in The American Journal of Gastroenterology.
MD Magazine online (3/14) 
LinkedIn Twitter Facebook Email
Industry News & Practice
HTG Molecular enters $40M stock sale agreement with Cowen
HTG Molecular Diagnostics has agreed to sell $40 million of its common stock to or through Cowen. HTG intends to use net proceeds as working capital, for general corporate purposes and potentially for investments or acquisitions.
GenomeWeb Daily News (free registration) (3/13) 
LinkedIn Twitter Facebook Email
Government & Regulatory
CE mark granted to Personal Genome Diagnostics' liquid biopsy test
Personal Genome Diagnostics announced that its PGDx Elio Plasma Resolve liquid biopsy test has been given the CE mark. The test uses next-generation sequencing to detect amplifications, rearrangements, small insertions and deletions, and microsatellite instability in circulating cell-free DNA from plasma samples to help in cancer patients' therapy selection.
GenomeWeb Daily News (free registration) (3/14) 
LinkedIn Twitter Facebook Email
Expanded indication for hemophilia A therapy approved by EC
Roche Holding and Chugai Pharma UK announced that Hemlibra, or emicizumab, a treatment to prevent bleeding episodes in patients with hemophilia A with factor VIII inhibitors, was approved by the European Commission for treatment of patients with severe hemophilia without factor VIII inhibitors.
PharmaTimes online (UK) (3/14) 
LinkedIn Twitter Facebook Email
Association News
AABB to host eCast on lessons learned from the Serious Hazards of Transfusion (SHOT) program
AABB will host an eCast, "Serious Hazards of Transfusion: Lessons Learned," on Wednesday, March 20, at 2 p.m. Eastern Time. In this program, Paula Bolton-Maggs, DM, FRCP, former medical director of the UK National Haemovigilance Scheme, Serious Hazards of Transfusion (SHOT), will discuss the origins of the SHOT program and describe how hemovigilance efforts have made transfusions safer. Bolton-Maggs will also explore the types of transfusion errors that persist and explain the importance of the bedside checklist in preventing transfusion errors.
LinkedIn Twitter Facebook Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
We speak of educating our children. Do we know that our children also educate us?
Lydia Sigourney,

March is Women's History Month

LinkedIn Twitter Facebook Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information